Skip to main content

Table 1 The frequency of the different dhfr/dhps multiple mutations (multiplicity of mutations, MOM), in parasite infections obtained from patients with different treatment outcome, ACR and TF, following SP and CQ therapy, and the overall prevalence rate of MOM and the corresponding mutation/TF ratio.

From: The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics

Multiplicity of mutation (MOM) Frequency of cumulative MOM Overall prevalence of cumulative MOM Mutation/TF ratio (GRI)
  ACR (n,78) TF (n,75) P-value Chi-Square measured N1 = 153 calculated N2 = 231  
Null (wild) 0.038 (3) 0.013 (1) 0.640 2.6% (4) 03% (7)  
Single 0.962 (75) 0.987 (74) 0.640 97.4% (149) 97.0% (224) 2.74
Double 0.910 (71) 0.973 (73) 0.189 94.1% (144) 93.1% (215) 2.63
Triple 0.846 (66) 0.907 (68) 0.374 87.6% (134) 86.6% (200) 2.45
Quadruple 0.679 (53) 0.800 (60) 0.131 73.9% (113) 71.9% (166) 2.03
Quintuple 0.103 (8) 0.160 (12) 0.416 13.1% (20) 12.1% (28) <1
  1. ACR, adequate clinical response; TF, treatment failure; MOM, multiplicity of mutations; Mutation/TF ratio = prevalence of MOM (calculated)/TF rate (35.4)]. N1, number of genotyped samples; N2, total number of samples; GRI, genotype-resistance index